ライフサイエンスコーパス: haematological

1 7%]), pain (122/472 [26%] vs 135/468 [29%]), haematological (124/472 [26%] vs 73/468 [16%]), and gast

2 ith most of the grade 3 adverse events being haematological (45%).

3 Pegylated interferon alfa-2a induced haematological (66 [80%] of 83 patients) and molecular r

4 Haematological abnormalities were common, including rais

5 * Anaemia is the most common haematological abnormality seen in systemic disorders.

6 peak) would be revealed when controlling for haematological adaptations.

7 Haematological adverse effects were more common with CD

8 control group), whereas the most common non-haematological adverse event was hypokalaemia (25 [17%]

9 mab group than in the placebo group included haematological adverse events (neutropenia in 44 [54%] o

10 INTERPRETATION: Despite an increase in haematological adverse events and second primary maligna

11 d grade 3-4 pain, and 12 (15%) had grade 3-4 haematological adverse events during chemoradiation.

12 The most common non-haematological adverse events included electrolyte distu

13 Grade 3-4 haematological adverse events occurred in 32 (14%) of 23

14 Grade 3-4 non-haematological adverse events occurring in more than one

15 The most frequent haematological adverse events of any grade were anaemia

16 The most common grade 3-4 haematological adverse events reported, irrespective of

17 Overall, the only grade 3 or 4 non-haematological adverse events that occurred in at least

18 olerated dose, the most common grade 3-4 non-haematological adverse events were hyperglycaemia (ten [

19 Frequent grade 3-4 non-haematological adverse events were hypertension (five [7

20 The most common grade 3-4 haematological adverse events were neutropenia (five [28

21 No grade 4 non-haematological adverse events were reported.

22 Frequencies of non-haematological adverse events were similar in the R-CHOP

23 The main grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), a

24 Haematological analysis was performed using a Sysmex XN-

25 18 (8%) haematological and 14 (6%) solid tumour second primary m

26 t in the gene SH2B3, is also associated with haematological and autoimmune disorders, suggesting that

27 ease is associated with a high prevalence of haematological and biochemical abnormalities, even in mi

28 tting, and few data exist for the associated haematological and biochemical abnormalities.

29 g reverse-transcriptase-PCR (RT-PCR) and for haematological and biochemical analysis.

30 IL-1Ra to prevent the clinical features and haematological and biochemical changes in patients with

31 rogression or intolerance), and had adequate haematological and biochemical parameters.

32 amount of parasite genome, and assessed for haematological and biochemical parameters.

33 nvulsants on event-free survival and risk of haematological and central-nervous-system (CNS) relapse,

34 treatment was assessed by questionnaires and haematological and cognitive tests, which were done befo

35 paired iron transport may contribute to both haematological and degenerative symptoms of ML4 patients

36 d Tumors version 1.1 (RECIST v1.1), adequate haematological and end-organ function, and no autoimmune

37 mors version 1.1 (RECIST v1.1), and adequate haematological and end-organ function.

38 Three haematological and five solid tumour second primary mali

39 lignant disorders and other life-threatening haematological and genetic diseases.

40 oss of Nrbp1 results in tumourigenesis, with haematological and intestinal tumours predominating, and

41 nervous system (peripheral and central) and haematological and lymphoproliferative disorders.

42 ylated interferon alfa-2a can induce durable haematological and molecular responses in patients with

43 lenalidomide group, compared with three (1%) haematological and nine (4%) solid tumour second primary

44 Oral eliglustat maintained haematological and organ volume stability in adults with

45 an uncertain risk of tissue contamination in haematological and other malignancies.

46 y Group performance status 0-2, and adequate haematological and renal function.

47 ients assigned temozolomide, and were mainly haematological and reversible.

48 in a large number of malignancies, including haematological and solid cancers.

49 nesis, progression, and prognosis of various haematological and solid tumours.

50 ary reports of the use of valproate in human haematological and solid tumours.

51 Biochemical, haematological, and immunological profiles were examined

52 sorder in adults with cancer in oncological, haematological, and palliative-care settings.

53 with cancer, including those in oncological, haematological, and palliative-care settings.

54 toxicity in zebrafish embryos, do not cause haematological, biochemical or histological abnormalitie

55 Patients who died from haematological cancer (PRs 0.46-0.52), who were single,

56 overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mou

57 ent, along with known at risk groups such as haematological cancer, lung cancer, older age, and depri

58 6-2.04]; findings previously published), and haematological cancers (1.30 [1.11-1.53]).

59 nt increases in total (1.21 [1.06-1.39]) and haematological cancers (1.35 [1.01-1.81]).

60 these data suggest a potential for treating haematological cancers harbouring U2AF1 mutations with p

61 s, although some have been more promising in haematological cancers.

62 sults indicate that, when coping with severe haematological challenges, local regulation of skeletal

63 on skin and bone tissues besides than on the haematological compartment.

64 ficiency, liver involvement, neurological or haematological complications, uteroplacental dysfunction

65 lobulin (ATG) but neither relapse nor clonal haematological complications.

66 Clinical and haematological consequences of T-cell depletion, and in-

67 Although Ppara(-/-) mice show no haematological difference from wild-type mice in both no

68 f IMN and one died from complications of the haematological disease.

69 tant approach in the management of malignant haematological disease.

70 providing meaningful clinical insights into haematological diseases, and these could not be revealed

71 ignalling, defining an atypical form of this haematological disorder rapidly progressing to acute mye

72 ell disease is a common and life-threatening haematological disorder that affects millions of people

73 c lymphocytic leukaemia (CLL) is a malignant haematological disorder that remains mostly incurable; m

74 ing CCAM, we have analysed transcriptomes of haematological disorders and those of normal haematopoie

75 ular disorders, and liver disease in Europe; haematological disorders in North America; and respirato

76 ition and wasting, parasitic infections, and haematological disorders in the Africa region; respirato

77 fic cellular approaches for the treatment of haematological disorders requiring myelosuppressive regi

78 39 patients with malignant haematological disorders were infused with either bone m

79 ssion, followed by malnutrition and wasting, haematological disorders, and, in the African region, ma

80 racterization of the molecular basis of many haematological disorders.

81 atopoietic stem cells could aid treatment of haematological disorders.

82 acterized mutations in the XPD gene have the haematological features of beta-thalassaemia trait, and

83 RECENT FINDINGS: This review explores the haematological features of Gaucher disease in the contex

84 n predict CNS events better than clinical or haematological features, or transcranial doppler sonogra

85 ife expectancy of 6 months or more; adequate haematological function for 28 days or more; and one or

86 The most common non-haematological grade 3 adverse events were fever (nine [

87 who received CRT plus cetuximab had more non-haematological grade 3 or 4 toxicities (102 [79%] of 129

88 openia after engraftment was the most common haematological grade 3-4 adverse event (nine) but was tr

89 Genetic, dermatological, haematological, granulomatous, immunosuppressive, and ne

90 Solid Tumors (RECIST) version 1.1, adequate haematological, hepatic, and renal function, and immune-

91 ) performance status of 0 or 1, and adequate haematological, hepatic, and renal function.

92 progression-free survival, overall survival, haematological improvement measured by haemoglobin, time

93 Sustained haematological improvement was noted in 72 (79%) of 91 p

94 n-free survival, overall survival, sustained haematological improvement, and immunological improvemen

95 modified International Working Group-defined haematological improvement-erythroid (HI-E), defined as

96 or worse adverse events in both groups were haematological, including anaemia (150 [48%] of 313 pati

97 when found in association with clinical and haematological indications of CML.

98 The increased risks noted for haematological, kidney, and pancreatic cancers need conf

99 tolerability, including adverse events, non-haematological laboratory grade 3-4 toxic effects, and c

100 For people with haematological malignancies (n=224), the most troublesom

101 age-specific tumour types, including several haematological malignancies and androgen receptor-positi

102 ges, TAMs, are an abundant part of solid and haematological malignancies and have been linked with pr

103 have demonstrated the involvement of GFI1 in haematological malignancies and have suggested that low

104 ic event linked to increased risk of primary haematological malignancies and increased all-cause mort

105 rent gene fusions, typically associated with haematological malignancies and rare bone and soft-tissu

106 tumour growth, have been identified in human haematological malignancies and solid cancers.

107 s with multiple myeloma, but also with other haematological malignancies and solid tumours.

108 hat PTEN plays a role in the pathogenesis of haematological malignancies and that it might be inactiv

109 essential for the treatment of patients with haematological malignancies and the recipients of stem-c

110 rch is required with regard to patients with haematological malignancies and/or receiving prophylacti

111 Patients with haematological malignancies are less likely to use palli

112 Tet2 mutations are drivers in haematological malignancies but Tet1 had an oncogenic ro

113 omplement conventional banding techniques in haematological malignancies by analysing 15 cases with u

114 myeloproliferative neoplasms are a group of haematological malignancies characterised by pathologica

115 d physical decline over time for people with haematological malignancies compared with people with so

116 tution, and activity against other solid and haematological malignancies has been established.

117 ated with substantial familial clustering of haematological malignancies indicated that this gene is

118 Community patients with haematological malignancies receiving palliative care ha

119 Haematological malignancies were defined by morphology c

120 s of the respiratory system or heart, or for haematological malignancies were found.

121 Adult patients with non-leukaemia haematological malignancies who had disease progression

122 gical roles of miRNAs in the pathogenesis of haematological malignancies will allow rational stratifi

123 with diseases such as solid-tumour cancers, haematological malignancies, and chronic digestive disea

124 tatus (patients with HIV, immunosuppression, haematological malignancies, and previous organ transpla

125 f the most effective immunotherapies against haematological malignancies, but significant clinical su

126 treatment of multiple sclerosis, psoriasis, haematological malignancies, Crohn's disease, and rheuma

127 ed an even greater relevance in the field of haematological malignancies, due to the already advanced

128 ell lines, while a smaller number of primary haematological malignancies, in particular NHLs, carries

129 n essential part of the treatment of cancer, haematological malignancies, marrow failure, and haemato

130 e reported single-agent activity in advanced haematological malignancies, mechanisms determining the

131 ncer cell lines and primary samples of human haematological malignancies, reveal that senescence-asso

132 tations frequently occur in various types of haematological malignancies, the mechanism by which they

133 the genetic lesions that characterize human haematological malignancies, thus often generating faith

134 emopoiesis have increased risk of developing haematological malignancies.

135 ich are recurrently deleted/mutated in human haematological malignancies.

136 mortality records to ascertain occurrence of haematological malignancies.

137 actic platelet transfusions in patients with haematological malignancies.

138 ns or point mutations is a frequent event in haematological malignancies.

139 disrupted in several human tumours including haematological malignancies.

140 of diagnostic and prognostic importance for haematological malignancies.

141 are members of common oncogenic pathways in haematological malignancies.

142 (median age 45.8 years [IQR 33.2-55.5]) with haematological malignancies.

143 recommended dose of OTX015 in patients with haematological malignancies.

144 atients were aged 18-55 years, had high-risk haematological malignancies.

145 ty was noted in 23 (49%) of 47 patients with haematological malignancies.

146 palliative care service use by patients with haematological malignancies.

147 e patients were aged 16 to 70 years with any haematological malignancy and a Karnofsky score of at le

148 ultiple myeloma is the second most prevalent haematological malignancy and is incurable.

149 OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells,

150 ting a novel TET2 loss-mediated mechanism of haematological malignancy pathogenesis.

151 l acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosi

152 d first-line treatment in patients with this haematological malignancy.

153 ency with age and predisposes individuals to haematological malignancy.

154 Children with cancer, patients with haematological malignant disease, and patients treated b

155 Multiple myeloma is the second most common haematological malignant disease, but cannot be cured wi

156 ted adults (aged >/=18 years) with high-risk haematological malignant diseases who were candidates fo

157 oliferative disorders form a range of clonal haematological malignant diseases, the main members of w

158 for breast cancer, ovarian cancer, and some haematological malignant diseases.

159 an intensive therapy used to treat high-risk haematological malignant disorders and other life-threat

160 ndard myeloablative conditioning therapy for haematological malignant disorders has been limited by s

161 tanding of the graft-versus-tumour effect in haematological malignant disorders have led to the use o

162 Postintervention haematological measures of iron status were significantl

163 Skin moisture, age, haematological measures, nutrition and general health st

164 ety assessments included renal, hepatic, and haematological monitoring and recording of adverse event

165 le the application of PGD to the less common haematological mutations, and the diagnosis of nonaffect

166 Grade 3 or 4 haematological (odds ratio 1.49-8.60) and gastrointestin

167 are often associated with increased risk of haematological or neurological toxicity.

168 s analysis, including standard chemistry and haematological panels, were taken on each treatment day.

169 Secondary endpoints included haematological parameters and a safety analysis of adver

170 aluate the effect of thermal injury on novel haematological parameters and to study their association

171 t responses, in terms of symptom control and haematological parameters, are usually obtained.

172 modified Rankin Scale (mRS), Barthel Index, haematological parameters, serious adverse events and de

173 progenitor proliferation contributes to the haematological phenotype of SDS.

174 OTX015 is active in haematological preclinical entities including leukaemia,

175 e populations self-maintain independently of haematological progenitors prompted us to consider organ

176 lowing 6 weeks of ET is mainly determined by haematological rather than skeletal muscle adaptations.

177 s complete remission (CR) or CR with partial haematological recovery of peripheral blood counts (CRh)

178 46 (18%) complete remission with incomplete haematological recovery, and 25 (10%) partial remission

179 n was given every 21 days if patients showed haematological recovery, whereas the rapid regimen was g

180 imen was given every 10 days irrespective of haematological recovery.

181 rd ratio 2.67 [95% CI 1.50-4.76]; p=0.0009), haematological relapse (3.40 [1.69-6.88]; p=0.0006), and

182 kaemia had high risk of remission failure or haematological relapse (72% [95% CI 40-100] at 10 years

183 osinophilia, three had complete clinical and haematological remission.

184 progressive metastatic disease, and adequate haematological, renal, and hepatic function.

185 FISH analysis of TOP2A status; and adequate haematological, renal, hepatic, and cardiac function.

186 26 (39%) of 66 haematological responders and 25 (71%) of 35 molecular r

187 The primary endpoint was haematological response (no longer meeting criteria for

188 The primary endpoint was haematological response at 3 months after infusion.

189 14 patients (56%; 95% CI 35-76) had a haematological response at 3 months.

190 elapsed and refractory disease suggests that haematological response can be achieved without continue

191 Complete haematological response was defined as normalisation of

192 study was the proportion of patients with a haematological response.

193 dies contribute to a deeper understanding of haematological responses in patients with chronic infect

194 Haematological responses were assessed every 3-6 months

195 h normal serum interleukin 5 showed complete haematological responses; a female patient who did not r

196 e the biological relations, and describe the haematological risk factors for oxyhaemoglobin desaturat

197 (HR 1.1 [95% CI 0.62-2.00]; p=0.72), and of haematological second primary malignancies were 3.1% (95

198 cies, solid second primary malignancies, and haematological second primary malignancies, and were ana

199 lidomide had an increased risk of developing haematological second primary malignancies, driven mainl

200 [95% CI 0.33-2.24]; p=0.76) did not increase haematological second primary malignancy risk versus mel

201 plus oral melphalan significantly increased haematological second primary malignancy risk versus mel

202 no significant differences were seen in any haematological, serum chemistry, or radiological assessm

203 duals across 14 countries in oncological and haematological settings.

204 inst a broad range of cancers, including non-haematological solid tumours.

205 Primary outcomes were infant haematological status and iron status at 6 months of age

206 -weight, full-term infants improved iron and haematological status up to 6 months of age.

207 ry was measured with ultrasound, Doppler and haematological techniques.

208 verse events were fatigue (six patients) and haematological (ten patients).

209 he most common grade 3-4 adverse events were haematological; the most common of these was grade 4 neu

210 intermittent treatment had grade 3 or worse haematological toxic effects (72 [15%] vs 60 [12%]), whe

211 than in the capecitabine group had grade 3-4 haematological toxic effects (seven [18%] vs none, p=0.0

212 fects (seven [18%] vs none, p=0.008) and non-haematological toxic effects (ten [26%] vs four [12%], p

213 yelofibrosis who had suboptimal responses or haematological toxic effects with ruxolitinib.

214 the phase 2 portion of the study, grade 3-4 haematological toxicities included neutropenia (29 patie

215 Grade 3/4 haematological toxicities were rare.With Gem/Carb regime

216 t [28%]), infections (30 [54%] vs 19 [66%]), haematological toxicity (28 [50%] vs five [17%]), and ge

217 [11%]), infection (42 [19%] vs 22 [10%]) and haematological toxicity (48 [22%] vs 27 [12%]) were repo

218 2.04, 1.49-2.78, p<0.0001, respectively) and haematological toxicity (adjusted RR 9.76, 95% CI 3.03-3

219 a (13 [5%] vs none) but reduced incidence of haematological toxicity (grade >/= 3 neutropenia 35 [13%

220 cer therapies, such as chemoradiation, cause haematological toxicity primarily by activating the tumo

221 as associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the

222 ological toxicity was uncommon; as expected, haematological toxicity was more common in patients trea

223 Grade 4 haematological toxicity was more frequent in patients tr

224 Grade 4 non-haematological toxicity was uncommon; as expected, haema

225 xed 18) due to combined gastrointestinal and haematological toxicity.

226 reek population to 4.6% in the isolate) with haematological traits, for example, with mean corpuscula

227 rare cancers, with the largest increases for haematological tumours and sarcomas.

228 cy endpoint was percentage of patients whose haematological variables and organ volumes remained stab

229 Haematological variables improved slightly.

230 and at months 6 and 12, and biochemical and haematological variables monthly, including chitotriosid

231 Erythrocyte-endothelial adhesion and routine haematological variables were assessed.

232 Among haematological variables, sleeping SaO2 correlated only